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Background
The medicines for peptic ulcer and gastro-esophageal
reflux disease (ATC subgroup A02B) are among the
most commonly prescribed class of drugs. The aim of
this study was to analyze the pattern of consumption of
histamine H2 receptor antagonists (H2RAs) and proton
pump inhibitors (PPIs) in Serbia in 2010 in comparison
with Croatia and Sweden.
Methods
The data on the consumption of medicines have been
provided from the databases of the national regulatory
agencies. The results were expressed as the number of
defined daily doses per 1000 inhabitants per day (DID).
A qualitative analysis was carried out according to the
drug utilization 90% (DU90%) approach.
Results
The overall consumption of medicines from A02B sub-
group in 2010 in Serbia was 22.9 DID, whereas in Croatia
and Sweden was 32.8 DID and 48.6 DID, respectively. In
Serbia, H2RAs accounted for 71.8% (16.5 DID) of medi-
cines used within A02B subgroup, while in Croatia
H2RAs accounted for 37.3% (12.2 DID) and in Sweden
2.2% (1.1 DID). In the same year, the utilization of PPIs
in Serbia (6.5 DID) was more than three times lower
than in Croatia (20.6 DID) and more than seven times
lower than in Sweden (47.3 DID). The bulk of prescrip-
tion (DU90%) was made up of 3 (out of 7) medicines in
Serbia, 5 (out of 8) medicines in Croatia and 5 (out of 14)
medicines in Sweden. The most frequently used medicine
from the A02B subgroup in Serbia was ranitidine (56.0%,
i.e. 12.8 DID), in Croatia pantoprazole (36.5%, i.e.12.0
DID) and in Sweden omeprazole (81.3%, i.e. 39.0 DID).
Conclusions
The overall utilization of the medicines for peptic ulcer
and gastro-esophageal reflux disease was notably lower in
Serbia in comparison with Croatia and Sweden. Besides
the quantity, the pattern of use showed remarkable differ-
ences. Most commonly used medicines from the A02B
subgroup in Serbia were H2RAs whereas in Croatia and
Sweden were PPIs. These findings suggest that implemen-
tation of pharmacotherapeutic guidelines in Serbia is
needed in order to achieve harmonization in prescribing
practice.
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